Medicare negotiated palbociclib down 50% ($15,741 to $7,871 per month, effective 2027), the first direct government price control on a CDK4/6 inhibitor, while elacestrant's cost-effectiveness sits orders of magnitude above the $150,000/QALY threshold.
Every approved oral agent in HR+/HER2- metastatic disease is self-administered and therefore reimbursed under Medicare Part D, not Part B, so access is governed by formulary tier, prior authorization and step edits rather than buy-and-bill. The dominant 2025-2027 access event is the Inflation Reduction Act: CMS selected palbociclib (Ibrance) for the second cycle of Medicare drug price negotiation (IPAY 2027), with the negotiated price set at $7,871 for a 30-day supply against a $15,741 list price, a roughly 50% reduction taking effect in 2027. This is the first HR+/HER2- oncology agent subject to direct Medicare price-setting and it resets the class economics; competitor CDK4/6 inhibitors (ribociclib, abemaciclib) are not on the current selected list.
For the newer biomarker-targeted agents, access is gated twice: by a required companion-diagnostic result and by payer value scrutiny. Elacestrant coverage is contingent on a confirmed ESR1 mutation, alpelisib on a PIK3CA mutation, and capivasertib on an AKT-pathway alteration. On value, an independent US-payer cost-effectiveness analysis found elacestrant far exceeded the $150,000/QALY willingness-to-pay threshold, at $8.67M/QALY versus standard of care overall and $2.9M/QALY versus fulvestrant in the ESR1-mutant subgroup (PMID 38169749), while ICER's 2025 Launch Price report put elacestrant's annual list price at about $259,880 (net ~$233,892). The payer strategy is therefore mutation-gated utilization management on top of a Part D benefit whose ceiling is increasingly defined by IRA negotiation.
US access levers for HR+/HER2- oral therapy: IRA price-setting, ICER value verdicts and biomarker-gated Part D coverage.
| Access dimension | US status / figure | Source |
|---|---|---|
| IRA Medicare negotiation | Palbociclib (Ibrance) selected for IPAY 2027; negotiated $7,871 vs $15,741 list (-50%), effective 2027 | CMS IPAY 2027 fact sheet / OncLive 2025 |
| CDK4/6 class list price anchor | ~$15,741 per 30-day supply (palbociclib list price) | CMS IPAY 2027 fact sheet |
| Oral SERD price | Elacestrant (Orserdu) ~$259,880/yr list; ~$233,892 net | ICER 2025 Launch Price & Access Report |
| Cost-effectiveness, elacestrant | $8.67M/QALY vs SOC overall; $2.9M/QALY vs fulvestrant in ESR1-mut; both above $150K WTP | US-payer CEA, Front Oncol 2023 (PMID 38169749) |
| Biomarker-gated prior authorization | Elacestrant (ESR1), alpelisib (PIK3CA), capivasertib (AKT-pathway) require companion-diagnostic-confirmed mutation for coverage | FDA labels / NCCN Breast Cancer guideline |
| Benefit routing & utilization management | All six oral agents are self-administered -> Medicare Part D (not Part B); prior authorization and step edits common commercially | CMS Medicare Part D / SAD exclusion framework |
Sources: IRA: CMS Medicare Drug Price Negotiation Program, Selected Drugs for IPAY 2027 (palbociclib negotiated $7,871 vs $15,741 list); OncLive coverage of second negotiation cycle. Elacestrant price: ICER 2025 Launch Price and Access Report (~$259,880 list / ~$233,892 net). Cost-effectiveness: US-payer analysis, Frontiers in Oncology 2023 (PMID 38169749: $8.67M/QALY overall, $2.9M/QALY ESR1-mut vs fulvestrant, WTP $150K). Coverage mechanics: FDA labels, NCCN guideline, CMS Part D. Not IRA-selected: ribociclib, abemaciclib, elacestrant, alpelisib, capivasertib (verified against the CMS selected-drug list).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Palbociclib selection and 50% negotiated cut effective 2027 • Read-through risk to ribociclib and abemaciclib in future cycles
Delivers
- • Companion-diagnostic gating: ESR1, PIK3CA, AKT-pathway • Cost-effectiveness verdicts vs the $150K/QALY threshold
Delivers
- • All six oral agents route through Part D • Prior authorization, step edits and biomarker requirements
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why all six approved HR+/HER2- oral agents route through Medicare Part D, not Part B, since none require in-office administration
- How formulary tier, prior authorization and step edits, not buy-and-bill economics, govern commercial access to this class
- Why CMS selected palbociclib for IPAY 2027, cutting its price from $15,741 to $7,871 per 30-day supply, a roughly 50% reduction
- How ribociclib and abemaciclib remain off the current CMS selected-drug list despite sharing palbociclib's mechanism
- Why elacestrant, alpelisib and capivasertib coverage each require a confirmed companion-diagnostic mutation result before approval
- How mutation-gated prior authorization, not indication alone, determines which patients can access each biomarker-targeted agent
- Why elacestrant's $8.67M per QALY versus standard of care lands far above the $150,000 willingness-to-pay threshold
- How ICER's roughly $259,880 annual list price compares against the narrower $2.9M per QALY result in the ESR1-mutant subgroup
- How the CMS Medicare Drug Price Negotiation Program selected palbociclib for its second negotiation cycle, effective 2027
- Why this first HR+/HER2- oncology selection creates read-through risk for ribociclib and abemaciclib in future negotiation cycles
- Why mutation-gated utilization management now sits on top of a Part D benefit whose price ceiling is set by IRA negotiation
- How manufacturers and payers must plan around both companion-diagnostic gating and an expanding Medicare negotiation list
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Breast Cancer HR+/HER2- Payer & HTA sources: CMS Medicare Drug Price Negotiation Program, ICER reports, FDA labels, NCCN guidelines, and a peer-reviewed cost-effectiveness analysis.
- Palbociclib selected for IPAY 2027 Medicare negotiation; negotiated price $7,871 vs $15,741 list (~50% cut), effective 2027 (CMS; confirmed via CMS/OncLive).
- Ribociclib, abemaciclib, elacestrant, alpelisib and capivasertib are not on the current CMS selected-drug lists.
- Elacestrant cost-effectiveness $8.67M/QALY overall and $2.9M/QALY vs fulvestrant in ESR1-mut, above the $150K/QALY threshold (PMID 38169749).
- Elacestrant annual list price ~$259,880 (net ~$233,892), ICER 2025 Launch Price and Access Report.
- All six oral agents route through Medicare Part D as self-administered drugs (CMS).
Frequently asked questions
Commission this assessment
AXLRx delivers US Breast Cancer HR+/HER2- payer & hta built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.